| Literature DB >> 25385946 |
Abstract
Prevention of diabetic complications is mainly obtained through optimal control of blood glucose levels. With hypoglycemic drugs like beta-cell stimulating drugs and especially insulin, the limit to treatment is represented by hypoglycemia, a life-threatening occurrence that is dangerous itself and can induce fear of other episodes. Glucagon, injected subcutaneously (SC) or intramuscularly (IM), is the treatment of choice for severe hypoglycemia outside of the hospital setting. However, due to practical aspects such as preparation of solutions for administration and injection by untrained persons, there are obstacles to its routine use. This review focuses on the current status of alternative routes of administration of peptide hormones, and in particular the intranasal (IN) route of glucagon, as a promising approach for the treatment of severe hypoglycemia.Entities:
Keywords: diabetes; glucagon; hypoglycemia; insulin; intranasal; peptide hormones
Mesh:
Substances:
Year: 2014 PMID: 25385946 PMCID: PMC4495544 DOI: 10.1177/1932296814557518
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN: 1932-2968